and treatment, thereby advancing the progress of precision medicine
The FDA has responded with three waves of enforcement letters - September 2025, March 2026, and June 2026 - targeting telehealth companies for misleading GLP-1 marketing
GLP-1 insurance, approved Insurance said no
GLP1-S Research Applications (Benefits) GLP1-S has become a central focus of preclinical and non-clinical investigations due to its wide-ranging influence on metabolism, appetite, and endocrine pathways
Think about the week ahead wherell you be at mealtimes and whatll youll eat
( Differently, studies conducted in women with PCOS treated with DPP4is have shown a decrease in inflammatory cytokine expression and oxidative stress, and activation of the anti-apoptotic pathway, thus improving ovarian cycles and ovulation ( In summary, although the studies on this topic are scarce, a direct or indirect beneficial impact of DPP4is, even if mild, on testis function cannot be ruled out